Novelix Pharmaceuticals, Inc., a Delaware corporation, is a private, California-based biotechnology company committed to developing proprietary first-in-class, targeted small molecules for cancer therapy. Some of our drug candidates also show great promise beyond oncology indications. In 2006, its second year of operations, the company achieved profitability and became a clinical-stage animal health company. Most recently, it successfully completed a human pilot on one of its lead drug candidates. All of the Novelix small molecule drugs and platforms have been designed and created by the company’s founders and team members. The founders have worked closely with each other on related ventures over the last 15 years. Beyond its innovative compounds and experienced team, the company differentiates itself through a business model that reduces risk by evaluating its drug candidates not only in commonly used model systems but also in canine patients with spontaneously occurring tumors that more closely resemble human cancer. Novelix maximizes shareholder value by proactively pursuing early licensing opportunities. Novelix has selected three lead product candidates for further development.
